Buprenorphine and Potassium Oxybate: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Potassium Oxybate
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Buprenorphine (an opioid used for pain or opioid dependence) and potassium oxybate (Xywav, used for narcolepsy) both slow down the brain and nervous system. When you take them together, those calming effects can stack up. This can make you very sleepy, slow your breathing, drop your blood pressure, cause fainting, and in the worst cases it can be life-threatening.
The good news is your care team can manage this. Please don't stop or change either medicine on your own. Tell your pharmacist and doctor that you take both, and ask what warning signs (like extreme drowsiness or slow, shallow breathing) to watch for. They may adjust your doses and monitor you more closely to keep you safe.
Mechanism: Additive CNS and respiratory depression. Buprenorphine (a partial mu-opioid agonist) and potassium oxybate (a CNS depressant/GHB analog) act on distinct pathways but produce pharmacodynamic summation. Neither is a prodrug here; the concern is additive PD, not a PK/enzyme interaction.
Direction: Increased combined CNS/respiratory depressant effect.
Evidence: Theoretical, but severity rated major; onset unspecified.
- Combination is generally not recommended.
- If required, consider dose reduction or discontinuation of one or more CNS depressant (including the oxybate).
- For short-term/perioperative opioid need, consider interrupting oxybate therapy.
- Monitor mental status, respiratory rate, and BP; strongly consider prescribing naloxone.
What happens
An increased risk of CNS depression and clinically significant respiratory depression, obtundation, hypotension, profound sedation, syncope, and death
Interaction Deep Dive
Taking sodium oxybate or mixed oxybate salts together with other CNS depressants raises the likelihood of additive CNS depression along with clinically meaningful respiratory depression, obtundation, hypotension, profound sedation, syncope, and death. Should combined use of an oxybate with these CNS depressants nonetheless be necessary, clinicians should weigh reducing the dose or stopping one or more of the CNS depressant(s), oxybates included. Likewise, when an opioid must be used briefly (for example, in the post- or perioperative setting), pausing oxybate therapy should be weighed234. Where concurrent use cannot be avoided, watch for alterations in mental status and for respiratory depression, proceed with caution, and give strong consideration to prescribing naloxone so that opioid overdose can be treated on an emergency basis 1.
Why it happens (mechanism)
Additive CNS depression
How to manage this interaction
Your care team's usual approach here:
- They may decide this combination is best avoided, or they may adjust and individualize your doses (lowering one or more medicines) if you need both.
- If you need an opioid only for a short time (such as around surgery), they may temporarily pause your oxybate.
- They may monitor you more closely for drowsiness, slowed breathing, and low blood pressure.
- They may prescribe naloxone to have on hand for emergencies.
Keep taking both exactly as prescribed unless told otherwise, and check with your pharmacist or prescriber before making any changes. Ask them to review the timing and doses for you.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Buprenorphine and Potassium Oxybate together?
Buprenorphine and potassium oxybate together can dangerously stack up sedation and slow breathing, so this combination is usually avoided. If you need both, keep taking them as prescribed and have your care team adjust doses, monitor you closely, and consider naloxone. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Potassium Oxybate interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Potassium Oxybate interaction managed?
Your care team's usual approach here: They may decide this combination is best avoided, or they may adjust and individualize your doses (lowering one or more medicines) if you need both. If you need an opioid only for a short time (such as around surgery), they may temporarily pause your oxybate. They may monitor you more closely for drowsiness, slowed breathing, and low blood pressure. They may p… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Buprenorphine or Potassium Oxybate need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: SUBUTEX(R) sublingual tablets, buprenorphine sublingual tablets. Indivior Inc (per FDA), North Chesterfield, VA, 2021. DailyMed
- Product Information: XYWAV(R) oral solution, calcium, magnesium, potassium, sodium oxybates oral solution. Jazz Pharmaceuticals Inc (per manufacturer), Palo Alto, CA, 2023. DailyMed
- Product Information: XYREM(R) oral solution, sodium oxybate oral solution. Jazz Pharmaceuticals Inc (per manufacturer), Palo Alto, CA, 2023. DailyMed
- Product Information: LUMRYZ(TM) oral extended-release suspension, sodium oxybate extended-release suspension. Avadel CNS Phamaceuticals LLC (per FDA), Chesterfield, MO, 2024. DailyMed
Keep reading about Buprenorphine
Keep reading about Potassium Oxybate
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist